Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bionano Genomics, Inc. (NASDAQ: BNGO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer, Bionano submits annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K that describe its financial condition, results of operations, risk factors and material corporate events.
Bionano’s recent Forms 8-K include disclosures about quarterly financial results, such as reports for the second and third quarters of 2025, and about capital markets transactions, including a September 2025 public offering of common stock and Series E and Series F warrants. The company has also filed a registration statement on Form S-1 relating to offerings of common stock, pre-funded warrants and warrants, which outlines offering terms, risk factors and use of proceeds.
Through this page, users can review Bionano’s descriptions of its business as a provider of optical genome mapping (OGM) solutions, diagnostic services and software, as well as its discussion of revenue sources, cost structure and liquidity. Filings may also include information on shareholder votes, such as the corrected voting results reported in an 8-K/A filed in June 2025, and details of securities purchase agreements and engagement letters with placement agents for public offerings.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify topics such as OGM adoption, consumables and software utilization, capital raises and going concern considerations. Investors can use this resource to track Bionano’s Forms 10-K and 10-Q for comprehensive financial statements, Forms 8-K for event-driven updates, and registration statements for securities offerings, while AI-generated insights assist in understanding the implications of each filing.
Bionano Genomics, Inc. is calling its 2026 Annual Meeting of Stockholders for May 14, 2026 at 10:00 a.m. Pacific Time, to be held exclusively online via live audio webcast at www.proxydocs.com/BNGO.
Stockholders will vote on electing two Class II directors to serve until the 2029 annual meeting, an advisory approval of named executive officer compensation, and ratification of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board recommends voting “For” all three proposals. Stockholders of record as of March 19, 2026, when 11,091,615 shares of common stock were outstanding, are entitled to vote.
Bionano Genomics provides genome analysis solutions centered on optical genome mapping (OGM), nucleic acid purification, diagnostic services and VIA software. It focuses on structural variant detection in constitutional disease, cancer and cell and gene therapy research.
The company flags substantial doubt about its ability to continue as a going concern, citing recurring losses, negative cash flows and a need for significant additional capital, with potential outcomes including curtailing operations or liquidation. As of June 30, 2025, non‑affiliate equity market value was about $12.2 million, and as of March 19, 2026 there were 11,092,000 common shares outstanding.
Bionano reports an installed base of 387 OGM systems at December 31, 2025 and annual flowcell sales of 30,171, slightly below 2024. It highlights recent milestones including new VIA and Solve software advances, deployment of the Stratys system, and establishment of Category I CPT codes and Medicare payment determinations for OGM in hematologic malignancies and constitutional genetic disorders.
Bionano Genomics reported Q4 2025 revenue of $8.0M, down 3% from Q4 2024, with gross margin improving to 43%. For full-year 2025, revenue was $28.5M, a 7% decline from 2024 as instrument and discontinued clinical services revenue fell, partly offset by higher consumables and software revenue.
Full-year gross margin rose sharply to 46% from 1%, and operating expenses dropped 55% to $46.5M, reducing net loss to $26.4M from $112.0M. The company ended 2025 with $29.6M in cash, equivalents, investments and restricted short-term investments and guided 2026 revenue to $30–33M, with Q1 2026 guidance of $6.5–6.7M.
Bionano Genomics, Inc. Chief Medical Officer Alka Chaubey reported a small tax-related share disposition. On the vesting of a restricted stock unit (RSU) award granted on February 15, 2023, the issuer withheld 18 shares of common stock at $1.10 per share to cover tax obligations, leaving Chaubey with 644 directly owned shares.
The Principal Accounting Officer of Bionano Genomics, Inc., Mark Adamchak, reported a small tax-related share disposition. On February 15, 2026, 3 shares of common stock were withheld by the company at $1.10 per share to cover his tax obligations on a restricted stock unit (RSU) award that vested on that date. After this withholding, he directly owned 260 shares. This was an administrative tax-withholding disposition, not an open-market sale.
Bionano Genomics reported an insider equity transaction involving its General Counsel, Jonathan V. Dixon. On February 15, 2026, 6 shares of common stock were withheld by the company to cover tax obligations tied to a restricted stock unit award vesting, at a price of $1.10 per share. After this tax-withholding disposition, Dixon directly owns 263 shares of Bionano Genomics common stock.
Bionano Genomics, Inc. chief operating officer Mark Oldakowski reported an automatic share disposition related to tax withholding. On shares that vested from a restricted stock unit (RSU) award granted on February 15, 2023, the issuer withheld 20 shares of common stock on February 15, 2026 to cover his tax obligations, at an indicated value of $1.10 per share. After this tax-withholding disposition, Oldakowski directly owned 895 shares of Bionano Genomics common stock. This was not an open-market buy or sell order, but a routine settlement mechanism tied to equity compensation.
Bionano Genomics President and CEO R. Erik Holmlin reported a small tax-related share disposition. On the settlement of a restricted stock unit (RSU) award that vested on February 15, 2026, the issuer withheld 51 shares of common stock at $1.10 per share to cover his tax obligations, rather than selling them on the open market. After this withholding transaction, he directly holds 1,657 shares of Bionano Genomics common stock.
Bionano Genomics, Inc. received an updated ownership report from Lind Global Fund III and related parties. The reporting group, which includes Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton, reports beneficial ownership of 1,050,000 shares of common stock, representing 9.35% of the outstanding class as of December 31, 2025.
The position consists of 525,000 Series E warrants and 525,000 Series F warrants to purchase common stock. These warrants are subject to a 9.9% beneficial ownership cap, meaning they cannot be exercised if such exercise would push the holders’ ownership above that threshold. The reporting persons certify that the securities were not acquired to change or influence control of Bionano Genomics.